GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-  
B1347 Ritodrine HClSummary: β-2 adrenergic receptor agonist -  
B7027 CGH 2466 dihydrochlorideSummary: adenosine receptor antagonist -  
C3631 O-1821Summary: cannabidiol analog with close structural similarity to O-1918 which is a selective antagonist of abnormal cannabidiol -  
B2007 Pizotifen MalateTarget: 5-HT2 Receptors|D2 ReceptorsSummary: 5-HT receptor antagonist -  
B1346 Propranolol HClSummary: Competitive non-selective beta-adrenergic receptors inhibitor -  
B7000 2'-MeCCPASummary: A1 adenosine receptor agonist -  
C3573 4-Quinolone-3-Carboxamide CB2 LigandSummary: ligand of the CB2 receptor -  
B1754 Fenspiride HClSummary: α adrenergic and H1 histamine receptor antagonist -  
B1344 Phenylephrine HClSummary: Selective α1-adrenergic receptor agonist -  
B6995 SCH 58261Target: Adenosine A2A ReceptorsSummary: A2A adenosine receptor competitive antagonist 
